Nationally Recognized Expert in Dry Eye
Disease, Allergic Conjunctivitis, and Other Ocular Surface
Diseases
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases, today announced the appointment of Paul
Karpecki, O.D., FAAO, to the company’s Anterior Segment Scientific
Advisory Board (SAB).
Dr. Karpecki is Clinical Director, Corneal Services and Advanced
Ocular Surface Disease at Kentucky Eye Institute and a clinician
for Gaddie Eye Centers. He is an Associate Professor at the
Kentucky College of Optometry and the Medical Director for Keplr
Vision and the Dry Eye Institutes of Kentucky and Indiana. Dr.
Karpecki received a Doctor of Optometry from Indiana
University.
“Paul is a nationally recognized leader in the field of
optometry,” said Todd C. Brady, M.D., Ph.D., President and CEO of
Aldeyra. “His more than 20 years of expertise is expected to be
extremely valuable as we continue to advance reproxalap and our
novel RASP inhibitor platform toward NDA submission in dry eye
disease and allergic conjunctivitis.”
Dr. Karpecki is the Chief Medical Editor for Review of
Optometry, and has moderated or chaired the Congressional Hearing
on the Impact of Dry Eye Disease, the Tear Film and Ocular Surface
Society (TFOS) Symposium, and the Dry Eye Summit. He has served on
the International Task Force on Dry Eye and the TFOS DEWS II
Diagnostic Methodology sub-committee, and is a TFOS Global
Ambassador. Dr. Karpecki has authored more than 20 peer-reviewed
publications and more than 300 articles that have appeared in
non-peer reviewed journals, as well as seven book chapters.
Selected in 2015 by Optometric Management as one of the 20 most
influential individuals in Optometry, he has given more than 1,000
invited lectures.
“I’m honored to contribute my expertise to help inform and shape
Aldeyra’s strategy for reproxalap as well as future drug candidates
designed to address ocular surface disease,” Dr. Karpecki said.
“Reproxalap represents a novel therapeutic approach that has
demonstrated statistically significant and clinically relevant
activity in dry eye disease and allergic conjunctivitis. Given
reproxalap’s profile and unique mechanism of action, I believe that
it has the potential to be the next novel entrant in both of these
indications.”
Dr. Karpecki is the sixth member of Aldeyra’s Anterior Segment
SAB. The other members are: David Chu, M.D.; Edward J. Holland,
M.D.; Victor Perez, M.D.; John Sheppard, M.D.; and Joseph Tauber,
M.D.
About Aldeyra Therapeutics Aldeyra Therapeutics is a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases. Aldeyra's lead investigational drug
product candidates are potential first-in-class treatments in
development for dry eye disease, allergic conjunctivitis,
proliferative vitreoretinopathy, and Sj�gren-Larsson Syndrome. The
company is also developing other product candidates for retinal and
systemic inflammatory diseases.
Safe Harbor Statement This release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding Aldeyra's strategy, future operations, future financial
position, projected costs and expenses, prospects, plans, and
objectives and Aldeyra's plans and expectations for its product
candidates, including plans relating to product development and
commercialization. Aldeyra intends such forward-looking statements
to be covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by terms
such as, but not limited to, "may," "might," "will," "objective,"
"intend," "should," "could," "can," "would," "expect," "believe,"
"anticipate," "project," "on track," "scheduled," "target,"
"design," "estimate," "predict," "potential," "aim," "plan" or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. Such forward-looking
statements are based upon current expectations that involve risks,
changes in circumstances, assumptions and uncertainties. Aldeyra is
at an early stage of development and may not ever have any products
that generate significant revenue. All of Aldeyra's development
timelines may be subject to adjustment depending on recruitment
rate, regulatory review, preclinical and clinical results, and
other factors that could delay the initiation or completion of
clinical trials. Important factors that could cause actual results
to differ materially from those reflected in Aldeyra's
forward-looking statements include, among others, the timing of
enrollment, commencement and completion of Aldeyra's clinical
trials, the timing and success of preclinical studies and clinical
trials conducted by Aldeyra and its development partners; updated
or refined data based on Aldeyra's continuing review and quality
control analysis of clinical data, Aldeyra's ability to design
clinical trials with protocols and endpoints acceptable to
applicable regulatory authorities; delay in or failure to obtain
regulatory approval of Aldeyra's product candidates; the ability to
maintain regulatory approval of Aldeyra's product candidates, and
the labeling for any approved products; the risk that prior
results, such as signals of safety, activity or durability of
effect, observed from preclinical or clinical trials, will not be
replicated or will not continue in ongoing or future studies or
clinical trials involving Aldeyra's product candidates; the scope,
progress, expansion, and costs of developing and commercializing
Aldeyra's product candidates; uncertainty as to Aldeyra’s ability
to commercialize (alone or with others) Aldeyra's product
candidates following regulatory approval, if any; the size and
growth of the potential markets and pricing for Aldeyra's product
candidates and the ability to serve those markets; Aldeyra's
expectations regarding Aldeyra's expenses and revenue, the
sufficiency or use of Aldeyra's cash resources and needs for
additional financing; the rate and degree of market acceptance of
any of Aldeyra's product candidates; Aldeyra's expectations
regarding competition; Aldeyra's anticipated growth strategies;
Aldeyra's ability to attract or retain key personnel; Aldeyra’s
limited sales and marketing infrastructure; Aldeyra's ability to
establish and maintain development partnerships; Aldeyra’s ability
to successfully integrate acquisitions into its business; Aldeyra's
expectations regarding federal, state and foreign regulatory
requirements; regulatory developments in the United States and
foreign countries; Aldeyra's ability to obtain and maintain
intellectual property protection for its product candidates; the
anticipated trends and challenges in Aldeyra's business and the
market in which it operates; and other factors that are described
in the "Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of
Aldeyra's Annual Report on Form 10-K for the year ended December
31, 2018 and Aldeyra's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019, which are on file with the
Securities and Exchange Commission (SEC) and available on the SEC's
website at www.sec.gov. Additional factors may be set forth in
those sections of Aldeyra's Annual Report on Form 10-K for the year
ended December 31, 2019, expected to be filed with the SEC in the
first quarter of 2020.
In addition to the risks described above and in Aldeyra's other
filings with the SEC, other unknown or unpredictable factors also
could affect Aldeyra's results. No forward-looking statements can
be guaranteed, and actual results may differ materially from such
statements. The information in this release is provided only as of
the date of this release, and Aldeyra undertakes no obligation to
update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200128005159/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024